USA - NASDAQ:HTGM - US40434H3021 - Common Stock
HTGM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. HTGM has a bad profitability rating. Also its financial health evaluation is rather negative. HTGM is valied quite expensively at the moment, while it does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.69% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -35.3 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.3 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.48
-0.12 (-20%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.24 | ||
| P/tB | 2.24 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.69% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.1 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.28% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.3 | ||
| Altman-Z | -35.3 |
ChartMill assigns a fundamental rating of 2 / 10 to HTGM.
ChartMill assigns a valuation rating of 1 / 10 to HTG MOLECULAR DIAGNOSTICS (HTGM). This can be considered as Overvalued.
HTG MOLECULAR DIAGNOSTICS (HTGM) has a profitability rating of 1 / 10.
The financial health rating of HTG MOLECULAR DIAGNOSTICS (HTGM) is 1 / 10.